Cynthia M Dougherty1, Robb W Glenny2, Robert L Burr2, Gayle L Flo2, Peter J Kudenchuk2. 1. From Biobehavioral Nursing and Health Systems (C.M.D., R.L.B.), Division of Cardiology, Arrhythmia Services, Department of Medicine (C.M.D., P.J.K.), Division of Pulmonary and Critical Care, Departments of Medicine and Physiology and Biophysics (R.W.G.), University of Washington Seattle; and Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (G.L.F.). cindyd@uw.edu. 2. From Biobehavioral Nursing and Health Systems (C.M.D., R.L.B.), Division of Cardiology, Arrhythmia Services, Department of Medicine (C.M.D., P.J.K.), Division of Pulmonary and Critical Care, Departments of Medicine and Physiology and Biophysics (R.W.G.), University of Washington Seattle; and Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (G.L.F.).
Abstract
BACKGROUND: Despite its salutary effects on health, aerobic exercise is often avoided after receipt of an implantable cardioverter defibrillator (ICD) because of fears that exercise may provoke acute arrhythmias. We prospectively evaluated the effects of a home aerobic exercise training and maintenance program (EX) on aerobic performance, ICD shocks, and hospitalizations exclusively in ICD recipients. METHODS AND RESULTS: A total of 160 patients (124 men and 36 women) were randomly assigned who had an ICD for primary (43%) or secondary (57%) prevention to EX or usual care (UC). The primary outcome was peak oxygen consumption, measured with cardiopulmonary exercise testing at baseline and 8 and 24 weeks. EX consisted of 8 weeks of home walking for 1 h/d, 5 d/wk at 60% to 80% of heart rate reserve, followed by 16 weeks of maintenance home walking for 150 min/wk. Adherence to EX was determined from exercise logs, ambulatory heart rate recordings of exercise, and weekly telephone contacts. Patients assigned to UC received no exercise directives and were monitored by monthly telephone contact. Adverse events were identified by ICD interrogations, patient reports, and medical charts. ICD recipients averaged 55±12 years and mean ejection fraction of 40.6±15.7; all were taking β-blocker medications. EX significantly increased peak oxygen consumption (EX, 26.7±7.0 mL/kg per minute; UC, 23.9±6.6 mL/kg per minute; P=0.002) at 8 weeks, which persisted during maintenance exercise at 24 weeks (EX, 26.9±7.7 mL/kg per minute; UC, 23.4±6.0 mL/kg per minute; P<0.001). ICD shocks were infrequent (EX=4 versus UC=8), with no differences in hospitalizations or deaths between groups. CONCLUSIONS: Prescribed home exercise is safe and significantly improves cardiovascular performance in ICD recipients without causing shocks or hospitalizations. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00522340.
RCT Entities:
BACKGROUND: Despite its salutary effects on health, aerobic exercise is often avoided after receipt of an implantable cardioverter defibrillator (ICD) because of fears that exercise may provoke acute arrhythmias. We prospectively evaluated the effects of a home aerobic exercise training and maintenance program (EX) on aerobic performance, ICD shocks, and hospitalizations exclusively in ICD recipients. METHODS AND RESULTS: A total of 160 patients (124 men and 36 women) were randomly assigned who had an ICD for primary (43%) or secondary (57%) prevention to EX or usual care (UC). The primary outcome was peak oxygen consumption, measured with cardiopulmonary exercise testing at baseline and 8 and 24 weeks. EX consisted of 8 weeks of home walking for 1 h/d, 5 d/wk at 60% to 80% of heart rate reserve, followed by 16 weeks of maintenance home walking for 150 min/wk. Adherence to EX was determined from exercise logs, ambulatory heart rate recordings of exercise, and weekly telephone contacts. Patients assigned to UC received no exercise directives and were monitored by monthly telephone contact. Adverse events were identified by ICD interrogations, patient reports, and medical charts. ICD recipients averaged 55±12 years and mean ejection fraction of 40.6±15.7; all were taking β-blocker medications. EX significantly increased peak oxygen consumption (EX, 26.7±7.0 mL/kg per minute; UC, 23.9±6.6 mL/kg per minute; P=0.002) at 8 weeks, which persisted during maintenance exercise at 24 weeks (EX, 26.9±7.7 mL/kg per minute; UC, 23.4±6.0 mL/kg per minute; P<0.001). ICD shocks were infrequent (EX=4 versus UC=8), with no differences in hospitalizations or deaths between groups. CONCLUSIONS: Prescribed home exercise is safe and significantly improves cardiovascular performance in ICD recipients without causing shocks or hospitalizations. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00522340.
Authors: Christopher M O'Connor; David J Whellan; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston Miller; Jerome L Fleg; Kevin A Schulman; Robert S McKelvie; Faiez Zannad; Ileana L Piña Journal: JAMA Date: 2009-04-08 Impact factor: 56.272
Authors: Bruce L Wilkoff; Brian D Williamson; Richard S Stern; Stephen L Moore; Fei Lu; Sung W Lee; Ulrika M Birgersdotter-Green; Mark S Wathen; Isabelle C Van Gelder; Brooke M Heubner; Mark L Brown; Keith K Holloman Journal: J Am Coll Cardiol Date: 2008-08-12 Impact factor: 24.094
Authors: Katherine E Cutitta; Lawrence K Woodrow; Jessica Ford; Julie Shea; Avi Fischer; Garrett Hazelton; Samuel F Sears Journal: J Cardiopulm Rehabil Prev Date: 2014 Jul-Aug Impact factor: 2.081
Authors: S Schwarz; A Boscheri; J Christle; A Duvinage; K Esefeld; H Fricke; N Pitsch; A Pressler; M Weichenberger; M Halle Journal: Herz Date: 2016-03 Impact factor: 1.443
Authors: Kim M Nielsen; Ann-Dorthe Zwisler; Rod S Taylor; Jesper H Svendsen; Jane Lindschou; Lindsey Anderson; Janus C Jakobsen; Selina K Berg Journal: Cochrane Database Syst Rev Date: 2019-02-12
Authors: Daniel A Steinhaus; Steven A Lubitz; Peter A Noseworthy; Daniel B Kramer Journal: J Cardiopulm Rehabil Prev Date: 2019-09 Impact factor: 2.081
Authors: Randal J Thomas; Alexis L Beatty; Theresa M Beckie; LaPrincess C Brewer; Todd M Brown; Daniel E Forman; Barry A Franklin; Steven J Keteyian; Dalane W Kitzman; Judith G Regensteiner; Bonnie K Sanderson; Mary A Whooley Journal: J Cardiopulm Rehabil Prev Date: 2019-07 Impact factor: 2.081
Authors: Randal J Thomas; Alexis L Beatty; Theresa M Beckie; LaPrincess C Brewer; Todd M Brown; Daniel E Forman; Barry A Franklin; Steven J Keteyian; Dalane W Kitzman; Judith G Regensteiner; Bonnie K Sanderson; Mary A Whooley Journal: J Am Coll Cardiol Date: 2019-05-13 Impact factor: 24.094
Authors: Carolina Santiago de Araújo Pio; Gabriela Ss Chaves; Philippa Davies; Rod S Taylor; Sherry L Grace Journal: Cochrane Database Syst Rev Date: 2019-02-01